Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
LABP Stock Summary
Top 10 Correlated ETFs
LABP
In the News
Why Is Landos Biopharma (LABP) Stock Up 168% Today?
Landos Biopharma (NASDAQ: LABP ) stock is on the rise Monday after the company announced an acquisition deal with AbbVie (NYSE: ABBV ). AbbVie is acquiring Landos Biopharma for $20.42 per share in cash.
AbbVie to buy Landos to expand pipeline of immunity-related illnesses
AbbVie said on Monday it would acquire drug developer Landos Biopharma for up to $212 million as the Humira-maker aims to expand its pipeline of medicines to treat immune system-related illnesses.
Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn's and Colitis Organisation
Six Presentations Highlight Landos' Leadership in Targeting Immunometabolic Pathways as Novel Treatments for Autoimmune Diseases with Focus on Ulcerative Colitis Six Presentations Highlight Landos' Leadership in Targeting Immunometabolic Pathways as Novel Treatments for Autoimmune Diseases with Focus on Ulcerative Colitis
Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will present additional findings from its Phase 1b study of NX-13 for the treatment of ulcerative colitis (UC), including detailed results on the rapid symptomatic relief and improvement in multiple clinical biomarkers observed in the study, at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting, being held October 20-25 in Vancouver, Canada.
Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will participate at the Jefferies Healthcare Conference, to be held from June 7-9, 2023 in New York, NY.
3 Top Biotech Penny Stocks Under $3 To Watch Right Now
Biotech penny stocks to watch right now. The post 3 Top Biotech Penny Stocks Under $3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.
Landos Biopharma, Inc.'s (LABP) CEO Tim Mayleben on Q3 2021 Results - Earnings Call Transcript
Landos Biopharma, Inc.'s (LABP) CEO Tim Mayleben on Q3 2021 Results - Earnings Call Transcript
Should You Buy Landos Biopharma (LABP) Ahead of Earnings?
Landos Biopharma (LABP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus
Phase 1 trial initiation expected before yearend with topline results in 1H 2022
LABP Financial details
LABP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 4.79 | 0 | 0 | |
Net income per share | -4.27 | -7.7 | -10.18 | -0.94 | 0 | |
Operating cash flow per share | -3.03 | -5.86 | -7.21 | -1.14 | 0 | |
Free cash flow per share | -3.08 | -5.91 | -7.32 | -1.14 | 0 | |
Cash per share | 15.32 | 7.18 | 24.2 | 1.1 | 0.01 | |
Book value per share | -7.84 | -13.79 | 20.31 | 0.97 | 0.01 | |
Tangible book value per share | -7.84 | -13.79 | 20.31 | 0.97 | 0.01 | |
Share holders equity per share | -7.84 | -13.79 | 20.31 | 0.97 | 0.01 | |
Interest debt per share | 0.09 | 0 | 0 | -0.01 | 0 | |
Market cap | 391.42M | 469.96M | 180.28M | 201.27M | 22.97B | |
Enterprise value | 381.61M | 467.54M | 171.98M | 164.63M | 22.93B | |
P/E ratio | -28.1 | -15.59 | -4.72 | -5.3 | -1.05K | |
Price to sales ratio | 0 | 0 | 10.02 | 0 | 0 | |
POCF ratio | -39.64 | -20.47 | -6.66 | -4.4 | -1.12K | |
PFCF ratio | -39.02 | -20.31 | -6.56 | -4.4 | -1.12K | |
P/B Ratio | -15.3 | -8.7 | 2.36 | 5.14 | 722.52 | |
PTB ratio | -15.3 | -8.7 | 2.36 | 5.14 | 722.52 | |
EV to sales | 0 | 0 | 9.55 | 0 | 0 | |
Enterprise value over EBITDA | -29.29 | -15.54 | -4.43 | -4.06 | -1.01K | |
EV to operating cash flow | -38.65 | -20.36 | -6.36 | -3.6 | -1.12K | |
EV to free cash flow | -38.04 | -20.2 | -6.25 | -3.6 | -1.12K | |
Earnings yield | -0.04 | -0.06 | -0.21 | -0.19 | 0 | |
Free cash flow yield | -0.03 | -0.05 | -0.15 | -0.23 | 0 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 0.75 | 0.08 | 0.21 | 0.9 | 1.65 | |
Current ratio | 16.56 | 2.71 | 5.55 | 7.39 | 6.09 | |
Interest coverage | -43.72 | 0 | 0 | 70.3 | 0 | |
Income quality | 0.73 | 0.76 | 0.7 | 1.17 | 0.93 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0.85 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 2.31 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0.01 | 0.02 | 0 | 0 | |
Capex to revenue | 0 | 0 | -0.02 | 0 | 0 | |
Capex to depreciation | -1.53 | -1.32 | -2.24 | -0.01 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0.23 | 0 | 0 | |
Graham number | 27.45 | 48.87 | 68.19 | 4.54 | 0.02 | |
ROIC | 0.54 | 0.57 | -0.51 | -1 | -0.71 | |
Return on tangible assets | -0.28 | -0.99 | -0.41 | -0.84 | -0.58 | |
Graham Net | -8 | -14.15 | 19.77 | 0.95 | 0 | |
Working capital | 47.08M | 18.85M | 75.54M | 39.13M | 31.79M | |
Tangible asset value | -25.58M | -54.02M | 76.27M | 39.13M | 31.79M | |
Net current asset value | -25.95M | -54.46M | 75.54M | 39.13M | 31.79M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 1.05M | 77.5K | 77K | 0 | 0 | |
Average payables | 1.87M | 5.33M | 10.76M | 8.17M | 2.41M | |
Average inventory | 0 | 699K | 699K | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 7.26K | 22.93K | 24.04K | 2.17K | 0 | |
Days of inventory on hand | 0 | 3.72K | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.05 | 0.02 | 0.02 | 0.17 | 0 | |
Inventory turnover | 0 | 0.1 | 0 | 0 | 0 | |
ROE | 0.54 | 0.56 | -0.5 | -0.97 | -0.69 | |
Capex per share | -0.05 | -0.05 | -0.12 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.98 | -0.96 | -0.86 | -0.63 | -0.94 | |
Operating cash flow per share | -1.88 | -0.92 | -1.26 | -0.82 | -0.36 | |
Free cash flow per share | -1.92 | -0.92 | -1.26 | -0.82 | -0.36 | |
Cash per share | 11.92 | 11.03 | 7.71 | 7.21 | 6.84 | |
Book value per share | 10.93 | 9.72 | 7.25 | 6.97 | 6.07 | |
Tangible book value per share | 10.93 | 9.72 | 7.25 | 6.97 | 6.07 | |
Share holders equity per share | 10.93 | 9.72 | 7.25 | 6.97 | 6.07 | |
Interest debt per share | 0.02 | -0.75 | -0.07 | 0.09 | -0.11 | |
Market cap | 26.17M | 20.13M | 19.32M | 26.13M | 24.09M | |
Enterprise value | -2.71M | -16.51M | -25.92M | -17.91M | -18.32M | |
P/E ratio | -0.82 | -1.3 | -0.86 | -1.67 | -1.03 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -3.46 | -5.44 | -2.37 | -5.11 | -10.81 | |
PFCF ratio | -3.39 | -5.43 | -2.37 | -5.11 | -10.81 | |
P/B Ratio | 0.59 | 0.51 | 0.41 | 0.6 | 0.64 | |
PTB ratio | 0.59 | 0.51 | 0.41 | 0.6 | 0.64 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0.35 | 2.54 | 4 | 4.07 | 3.52 | |
EV to operating cash flow | 0.36 | 4.46 | 3.17 | 3.51 | 8.22 | |
EV to free cash flow | 0.35 | 4.46 | 3.17 | 3.51 | 8.22 | |
Earnings yield | -0.3 | -0.19 | -0.29 | -0.15 | -0.24 | |
Free cash flow yield | -0.29 | -0.18 | -0.42 | -0.2 | -0.09 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 3.69 | 5.63 | 6.99 | 10.01 | 8.16 | |
Current ratio | 9.04 | 7.39 | 12.3 | 15.35 | 7.77 | |
Interest coverage | -116.85 | 2.17 | 14.56 | -7.97 | 7.9 | |
Income quality | 0.96 | 0.71 | 1.35 | 1.3 | 0.38 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 22.06 | 14.52 | 11.86 | 9.95 | 11.35 | |
ROIC | -0.18 | -0.12 | -0.13 | -0.09 | -0.14 | |
Return on tangible assets | -0.16 | -0.09 | -0.11 | -0.08 | -0.14 | |
Graham Net | 10.56 | 9.51 | 7.07 | 6.72 | 5.94 | |
Working capital | 44.01M | 39.13M | 47.02M | 43.27M | 37.66M | |
Tangible asset value | 44.01M | 39.13M | 47.02M | 43.27M | 37.66M | |
Net current asset value | 44.01M | 39.13M | 47.02M | 43.27M | 37.66M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 3.96M | 3.32M | 2.87M | 1.66M | 1.08M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.18 | -0.1 | -0.12 | -0.09 | -0.16 | |
Capex per share | -0.03 | 0 | 0 | 0 | 0 |
LABP Frequently Asked Questions
What is Landos Biopharma, Inc. stock symbol ?
Landos Biopharma, Inc. is a US stock , located in Blacksburg of Va and trading under the symbol LABP
What is Landos Biopharma, Inc. stock quote today ?
Landos Biopharma, Inc. stock price is $21.46 today.
Is Landos Biopharma, Inc. stock public?
Yes, Landos Biopharma, Inc. is a publicly traded company.